Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metabolic Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,801 result(s) found for: Metabolic Disease. Displaying page 1 of 91.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-001661-91 Sponsor Protocol Number: ML19569 Start Date*: 2016-12-09
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents
    Medical condition: Obesity in combination with metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10058097 Metabolic disorder PT
    19.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2022-000565-40 Sponsor Protocol Number: GLM101-002 Start Date*: 2022-11-04
    Sponsor Name:Glycomine, Inc
    Full Title: A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participa...
    Medical condition: PMM2-CDG
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10027426 Metabolic disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002562-42 Sponsor Protocol Number: TRCA-301E Start Date*: 2017-12-15
    Sponsor Name:Tricida, Inc.
    Full Title: A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis
    Medical condition: Metabolic acidosis associated with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027417 Metabolic acidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003533-16 Sponsor Protocol Number: UMCN-ONCO-201303 Start Date*: 2013-11-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Individualizing Pazopanib therapy by exploRing the role of Early metabolic responsE and drug exposure as a preDICTor for treatment outcome in patients with STS
    Medical condition: soft tissue sarcoma patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001550-34 Sponsor Protocol Number: TIGEM2-PDH Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: Studio clinico pilota per valutare l’efficacia della terapia con fenilbutirrato in pazienti affetti da deficit di piruvato deidrogenasi
    Medical condition: La Sperimentazione verrà eseguita su pazienti affetti da difetto dell’enzima piruvato deidrogenasi.I pazienti affetti da questa malattia manifestano aumento dei livelli di lattato nel sangue e nell...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10058097 Metabolic disorder PT
    20.1 10027433 - Metabolism and nutrition disorders 10000491 Acidosis lactic LLT
    20.0 10022891 - Investigations 10037677 Pyruvate LLT
    20.0 10022891 - Investigations 10023660 Lactate increased LLT
    20.0 10022891 - Investigations 10057975 Lactate pyruvate ratio PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002852-33 Sponsor Protocol Number: TOR-RIS-2004-01 Start Date*: 2005-04-13
    Sponsor Name:Dr. Jose Vicente Torregrosa Prats (fundacio clinic)
    Full Title: a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation Ensayo aleatorio, abierto ...
    Medical condition: bone metabolic pathology associated to kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058972 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003825-41 Sponsor Protocol Number: TRCA-301 Start Date*: 2017-09-21
    Sponsor Name:Tricida, Inc.
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis
    Medical condition: Metabolic acidosis associated with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027417 Metabolic acidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000677-77 Sponsor Protocol Number: S61338 Start Date*: 2018-06-26
    Sponsor Name:University Hospital Leuven
    Full Title: Novel strategies in weight loss in women with polycystic ovary syndrome: does the gut microbiome play a role?
    Medical condition: overweight and obese women with polycystic ovary syndrome (PCOS) at risk for metabolic syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003101-53 Sponsor Protocol Number: ARTinMMS Start Date*: 2007-01-10
    Sponsor Name:Karolinska Institutet
    Full Title: A randomised placebo controlled study of transdermal testosterone therapy (testosterone 1% hydroalcohol gel) to investigate the efficacy and safety in men with abdominal obesity, low testosterone l...
    Medical condition: The metabolic syndrome constitutes a cluster of risk factors for cardiovascular disease with increased morbidity and mortality. The metabolic syndrome is referred to as a concomitant occurrence of ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002037-38 Sponsor Protocol Number: NL44415.078.13 Start Date*: 2013-10-29
    Sponsor Name:
    Full Title: The effect of correction of metabolic acidosis in chronics kidney disease on intrarenal RAS activity.
    Medical condition: Metabolic acidosis in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002222-23 Sponsor Protocol Number: P170932J Start Date*: 2019-02-05
    Sponsor Name:APHP
    Full Title: Cobimetinib for BRAF-wild-type histiocytoses : a randomized, placebo-controlled, double blind study
    Medical condition: Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. patients with BRAF-wild type.
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022308-34 Sponsor Protocol Number: JW/IB/AG Start Date*: 2011-04-19
    Sponsor Name:Central Manchester Foundation Hospitals Trust
    Full Title: Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity
    Medical condition: Obesity and Metabolic Syndrome (combination of obesity, hypertension, raised blood glucose and cholesterol abnormalities)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    13.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002815-20 Sponsor Protocol Number: MET07 Start Date*: 2007-10-09
    Sponsor Name:Royal Surrey County Hospital
    Full Title: A Prospective Randomised Pilot Study of Metformin and Lifestyle Intervention in the Prevention of Metabolic Syndrome due to Androgen Deprivation Therapy in Prostate Cancer
    Medical condition: Patients with prostate cancer on androgen deprivation therapy (ADT). Randomisation between standard treatment with ADT only, and the additional use of metformin with dietary and exercise advice. Ai...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001186 Adenocarcinoma of prostate LLT
    9.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002095-10 Sponsor Protocol Number: MV-2-2017 Start Date*: 2017-09-13
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney D...
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004846-25 Sponsor Protocol Number: Pfizer-Prevenar13-2015 Start Date*: 2016-07-15
    Sponsor Name:Maastricht University
    Full Title: Immunization against oxLDL in patients with lysosomal lipid diseases and associated metabolic disorders
    Medical condition: Familial hypercholesterolemia Niemann-Pick disease type B (NPB) Niemann-Pick disease type C (NPC) Partial lipodystrophy in children and adults
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017051-10 Sponsor Protocol Number: 09-313 Start Date*: 2010-07-13
    Sponsor Name:UMC Utrecht
    Full Title: Metabolic adverse events before and after glucocorticoid pulse therapy in rheumatoid arthritis
    Medical condition: Patients with rheumatoid arthritis, who suffer from a exacerbation of disease can be included in this study. Exacerbation is defined as a Disease Activity Score of 5.1 or higher. Patients will be e...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060732 Rheumatoid arthritis flare up LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003430-85 Sponsor Protocol Number: OBERAL Start Date*: 2017-11-29
    Sponsor Name:Helsinki University Hospital
    Full Title: A randomized, open, parallel design study to evaluate the effect on liver fat, adipose tissue and metabolic parameters when switching a protease inhibitor or efavirenz to once daily raltegravir in ...
    Medical condition: Study subjects are HIV infected patients with BMI>25kg/m2 and who have at least one metabolic syndrome component or a fatty liver disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000619-42 Sponsor Protocol Number: PI14/00638 Start Date*: 2015-05-05
    Sponsor Name:FIBICO
    Full Title: An open, Phase II, clinical trial to evaluate the effectiveness of decreased intestinal absorption of phosphorus in the progression of renal disease in patients with metabolic syndrome
    Medical condition: Chronic kidney disease and metabolic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007276-41 Sponsor Protocol Number: Ram_GEP_1 Start Date*: 2008-05-13
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril
    Medical condition: healthy young males
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020875-22 Sponsor Protocol Number: MetSNS Start Date*: 2010-08-20
    Sponsor Name:RUNMC
    Full Title: In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resista...
    Medical condition: Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022489 Insulin resistance LLT
    12.1 10052066 Metabolic syndrome LLT
    12.1 10048554 Endothelial dysfunction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 06:19:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA